Does lurbinectedin compromise the immune system's ability to fight infections?

Does lurbinectedin weaken the immune system?

Lurbinectedin is a chemotherapy drug approved for certain lung cancers. It kills dividing cells, so it affects bone marrow where immune cells develop. This produces neutropenia, a drop in neutrophils that helps the body fight bacteria. Users often receive colony-stimulating factors to keep counts safe.

What happens if immune cell counts fall too low?

Low neutrophil counts raise infection risk. Patients must watch for fever or other signs of infection. If counts fall below 500 per microliter, doctors may hold doses or reduce strength. Colony-stimulating factors restore counts in most cases.

How does lurbinectedin compare with other chemotherapy agents?

Lurbinectedin has a similar neutropenia rate to topotecan. Data show 90 percent of patients develop any-grade neutropenia, 70 percent severe neutropenia. Similar rates appear in other approved chemotherapy options for same small-cell lung cancer indications.

When does the immune effect peak?

Neutrophil counts bottom out seven to fourteen days after each dose. Recovery takes another sieben to fourteen days. Jadelle-like patterns appear in lurbinectedin data, but lurbinectedin is not a hormonal contraceptive.

When does lurbinectedin patent expire?

Lurbinectedin patent expires in 2031. Biosimilars can enter once patent and exclusivity periods end. [1]

[1] https://www.drugpatentwatch.com